More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 56.63M
Licensing and royalty revenue 448K
Total revenue 57.08M
Research and development
General and administrative 4.46M
Total operating expenses 63.73M
Loss from operations -6.65M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 671K
Interest expense -4.96M
Gain (loss) on investments, net -260K
Loss before income tax expense
Income tax expense
Net loss
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)